# Veeva Systems

Type: Company (VEEV)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/veeva-systems
Canonical HTML page: https://getbiobrief.com/entity/veeva-systems

## Recent coverage (2 stories)

### Veeva Systems Drops 5.3% in Tech Sell-Off—A Buying Opportunity for Pharma SaaS?
2026-08-04 19:06:32 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Veeva Systems (VEEV) fell 5.3% to $201.56 during a broader software rout triggered by the Federal Reserve’s hawkish dot plot. The life-sciences cloud leader faces the same rate-driven multiple compression as other SaaS names, but its pharma client base and mission-critical R&D applications may insulate revenue, creating a potential long-term entry point for biotech investors.
Full story: https://getbiobrief.com/story/veeva-systems-fed-selloff-biotech-2026

### Eli Lilly and Veeva Lead 2026 Growth Outlook Amid AI-Driven Pharma Shift
2026-03-04 04:11:43 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

As market volatility persists in early 2026, Eli Lilly and Veeva Systems emerge as top growth picks driven by the obesity drug boom and AI integration. With Eli Lilly's tirzepatide securing its spot as the world's top-selling drug and new oral GLP-1s on the horizon, the pharmaceutical landscape is shifting toward tech-heavy, high-margin innovation.
Full story: https://getbiobrief.com/story/eli-lilly-veeva-2026-growth-outlook

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.